Skip to main content

Table 1 Baseline clinical characteristics of the study population and clinical characteristics stratified by event (Death/LVAD implantation/transplant) at 90 days.

From: Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy

Characteristic All Patients
(Number = 30)
No Event
(Number = 13)
Event
(Number = 17)
P a
Age 57 (50 - 65) 57 (45 - 63) 61 (53 - 65) 0.36
Male sex, number (%) 24 (77) 9 (69) 15 (88) 0.36
Ejection fraction, % 21 (17 - 30) 28 (19 - 35) 19 (17 - 25) 0.08
History, number (%)     
   Ischemic cardiomyopathy 14 (47) 6 (46) 8 (47) 0.82
   Prior myocardial infarction 8 (27) 5 (39) 3 (18) 0.24
   Hypertension 4 (17) 3 (23) 2 (12) 0.63
   Diabetes mellitus 11 (37) 5 (39) 6 (35) 1.00
   Ventricular tachycardia 12 (40) 2 (15) 10 (59) 0.03
   Resuscitated sudden cardiac death 5 (17) 1 (8) 4 (24) 0.36
   Smoking (past or present) 16 (53) 8 (62) 8 (47) 0.57
   Atrial fibrillation 11 (37) 3 (23) 8 (47) 0.26
   Chronic kidney disease 9 (30) 3 (23) 6 (35) 0.69
   Hypothyroidism 7(23) 2 (15) 5 (29) 0.43
Medications on Presentation, number (%)     
   β-blocker 24 (80) 11 (85) 13 (77) 0.67
   ACE Inhibitor 13 (43) 5 (39) 8 (47) 0.72
   ARB 7 (23) 3 (23) 4 (24) 1.00
   Aldosterone antagonist 21 (70) 8 (62) 13 (77) 0.44
   Loop diuretics 28 (93) 11 (85) 17 (100) 0.18
   Digoxin 9 (30) 2 (15) 7 (41) 0.23
Medications During Study, number (%)     
   Diuretics 29 (97) 12 (92) 17 (100) 0.43
   Afterload reducing agents 13 (43) 7 (54) 6 (35) 0.46
   Inotropic agents 25 (83) 9 (69) 16 (94) 0.14
Physical Examination     
   Heart rate, beats/min 78 (70 - 90) 84 (71 - 93) 74 (70 - 82) 0.17
   Systolic blood pressure, mmHg 97 (90 - 104) 99 (91 - 104) 96 (85 - 104) 0.37
   Body-mass index, kg/m2 25 (22 - 28) 26 (24 - 29) 24 (23 - 27) 0.25
Laboratory Results     
   Blood urea nitrogen, mg/dL 25 (20 - 39) 30 (18 - 45) 24 (20-40) 0.90
   Creatinine, mg/dL 1.3 (1.1 - 1.8) 1.2 (0.9 - 1.9) 1.4 (1.2 - 1.9) 0.32
   Hemoglobin, g/L 12.0 (10.1 - 12.7) 12.3 (11.9 - 12.7) 11.3 (9.8 - 12.7) 0.18
   Sodium, mmol/L 138 (133 - 140) 140 (138 - 141) 134 (132 - 138) 0.01
Hemodynamic Indices     
   Central venous pressure, mmHg 10 (8 - 17) 10 (8 - 14) 9 (8 - 17) 0.73
   Pulmonary artery systolic pressure, mmHg 52 (46 - 56) 55 (52 - 60) 48 (36 - 51) 0.01
   Pulmonary artery diastolic pressure, mmHg 23 (18 - 28) 26 (24 - 31) 21 (16 - 22) 0.01
   Pulmonary capillary wedge pressure, mmHg 24 (17 - 28) 25 (23 - 28) 23 (15 - 28) 0.31
   Systemic vascular resistance, dyn-s/cm5 1,366 (993 - 1,590) 1,484 (974 - 1,666) 1,281 (997 - 1,557) 0.65
   Cardiac index, L/min/m2 2.0 (1.7 - 2.4) 2.1 (1.7 - 2.4) 2.0 (1.8 - 2.3) 0.73
Biomarker Results     
   sST2, ng/mL 148 (88 - 226) 87 (66 - 145) 183 (112 - 258) 0.02
   NT-proBNP, pg/mL 5,205 (2,591 - 10,021) 4,437 (2,943 - 10,185) 5,388(2,287 - 13,840) 0.77
   hsTnI, ng/mL 0.10 (0.04 - 0.20) 0.03 (0.02 - 0.05) 0.05 (0.02 - 0.17) 0.32
   eTnI, ng/mL 49.9 (24.0 - 140.4) 29.6 (21.9 - 79.4) 60.6 (28.5 - 214.2) 0.20
   cys-C, ng/mL 1.85 (1.11 - 2.16) 1.42 (0.95 - 2.23) 1.93 (1.50 - 2.63) 0.27
   MPO, pM 860 (513 - 1353) 1,218 (588 - 1813) 803 (455 - 1138) 0.23
Prognostic Indices     
   SAPS II 22 (18 - 29) 21 (18 - 29) 23 (18 - 29) 0.78
  1. aP value for difference between those with an event and those without. Continuous variables are expressed as median and interquartile range. ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; BUN, blood urea nitrogen, cys-C, cystatin C; eTnI, experimental research prototype Troponin I; hsTnI, highly sensitive Troponin I; LVAD, left ventricular assist device; MPO, myeloperoxidase; NT-proBNP, amino terminal cleavage fragment of B-type natriuretic peptide; SAPS II, Simplified Acute Physiology Score II; sST2, soluble ST2.